Kalos Medical was selected as a participant in the 2023 Industrial Technology Innovation Project, administered by South Korea’s Ministry of Trade, Industry, and Energy. As a participant in the project, Kalos will be awarded a grant of KRW4.67 billion (approximately $3.5 million) over five years to accelerate development of its renal denervation medical device for the treatment of hypertension.

South Korean startup Kalos was selected as the R&D lead amongst a consortium of institutions chosen to collaborate in the Interventional Medical Device category. 

In addition to Kalos, members of the consortium include biomedical sensor developer MNTek, Korea Electronics Technology Institute (KETI), and Seoul National University Bundang Hospital. The consortium will combine MNTek's biomedical sensor technology with Korea Electronics Technology Institute's electronic medical device control system technology to enhance development of Kalos’ renal denervation medical device. Seoul National University Bundang Hospital will conduct animal studies to verify efficacy, safety, and usability, led by Professor Chae In-ho in the Cardiology Department.

Kalos Medical has developed DENEX, a medical device for the treatment of hypertension for renal denervation, the device includes three electrodes that are introduced into the rental artery through a catheter and deliver radio frequency energy to the arterial wall, thereby deactivating the renal nerves, the effect of which is the reduction of hypertension. Currently, Kalos Medical is conducting clinical trials in Korea and Europe.